Episode 9.6 New Birth Control Products and Other Updates

Antonia Roberts and Howard Herrell review several new articles: • Epifoam for postpartum pain lacks evidence of effectiveness compared to simple ice packs while costing nearly $100 per unit• AMH levels above 5.39 are associated with PCOS diagnosis, providing a specific threshold for clinical use• External aortic compression demonstrated as a life-saving technique during severe obstetric hemorrhage• Vaginal estrogen in breast cancer survivors shows no increased risk of cancer recurrence or mortality• Delayed cord clamping in preterm twins reduces mortality by 30% and significantly decreases transfusion needsThen they discuss new birth control options while questioning the value of expensive pharmaceutical products compared to established, less costly alternatives.• New birth control options like Balcoltra ($280/month), FemLyv ($215/month), and Nextstellis ($250/month) offer minimal innovation over generic alternatives costing $10-15/month• Marketing terms like "bioidentical" and "plant-based" are often misleading as all hormonal contraceptives are synthesized from plant precursors• Progestin-only pills like Slynd provide only marginal DVT risk reduction (5 vs 4 per 100,000 person-years) compared to low-dose combined pillsCheck our Instagram for more information and join us again in two weeks for our next episode.00:00:00 Introduction and Epifoam Discussion00:06:27 Financial Impact of Unnecessary Treatments00:11:09 AMH Levels for PCOS Diagnosis00:15:11 External Aortic Compression for Hemorrhage00:20:22 Vaginal Estrogen and Delayed Cord Clamping00:21:51 New Birth Control Products Overview00:31:05 Analyzing Dissolvable Birth Control Pills00:34:22 Slynd: Drosperinone-Only Pill Evaluation00:42:09 Nextstellis and "Bioidentical" Estrogen Claims00:56:37 History of Birth Control DevelopmentFollow us on Instagram @thinkingaboutobgyn.